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Objectives: Studies examining healthcare workers’ exposure to antineoplastic drugs have focused on the drug preparation or 
drug administration areas. However, such an approach has probably underestimated the overall exposure risk as the drugs need 
to be delivered to the facility, transported internally and then disposed. The objective of this study is to determine whether drug 
contamination occurs throughout a facility and, simultaneously, to identify those job categories that are potentially exposed.
Methods: This was a multi-site study based in Vancouver, British Columbia. Interviews were conducted to determine the depart-
ments where the drugs travel. Subsequent site observations were performed to ascertain those surfaces which frequently came 
into contact with antineoplastic drugs and to determine the job categories which are likely to contact these surfaces. Wipe sam-
ples were collected to quantify surface contamination.
Results: Surface contamination was found in all six stages of the hospital medication system. Job categories consistently found to 
be at risk of exposure were nurses, pharmacists, pharmacy technicians, and pharmacy receivers. Up to 11 job categories per site 
may be at risk of exposure at some point during the hospital medication system.
Conclusion: We found drug contamination on select surfaces at every stage of the medication system, which indicates the exis-
tence of an exposure potential throughout the facility. Our results suggest that a broader range of workers are potentially exposed 
than has been previously examined. These results will allow us to develop a more inclusive exposure assessment encompassing 
all healthcare workers that are at risk throughout the hospital medication system.
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Introduction
Antineoplastic (cytotoxic) drugs are widely used agents for 
the treatment of  cancer. Some of these drugs act by interfer-
ing directly with the deoxyribonucleic acid (or its synthesis) of 
tumour cells and thereby interrupt their growth. Unfortunately, 
antineoplastic drugs are generally non-selective and therefore 
normal (non-tumour) cells may also be damaged which, in 
turn, results in toxic effects [1]. Given this, there is a risk to 
healthcare workers who handle, prepare, and/or administer 
antineoplastic drugs.
Numerous studies have examined antineoplastic drug 
contamination in healthcare facilities. Studies from several 
countries have demonstrated surface contamination of biologi-
cal safety cabinets, countertops, cabinets and floors within the 
drug preparation area [2-6]. Detectable levels of environmental 
drug contamination have also been found in patient care areas 
where antineoplastic drugs are administered [7]. A recently 
published summary of the contamination levels found in the 
literature reported that cyclophosphamide (CP) ranged in con-
centration from not detected to 3,834 nanograms per square 
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centimeter (ng/cm2), which suggests that existing control mea-
sures are not effective in reducing contamination levels [8]. In 
the absence of any current occupational exposure limits for CP 
(and most other antineoplastic drugs), it is therefore important 
to minimize contamination.
A literature review revealed that these surface contamina-
tion studies have primarily focused on two departments within 
a healthcare facility - the pharmacy, where the drugs are pre-
pared, and the administration units where the prepared drugs 
are given to patients. The emphasis on these two departments 
is warranted since direct handling of  the drugs is expected 
during both preparation and administration. However, given 
the fact that the drugs need to be initially delivered to the phar-
macy, then transported to the wards and eventually disposed of 
as part of the hospital medication system (process flow of the 
drugs throughout a facility from cradle-to-grave), it is conceiv-
able that other areas of a healthcare facility may have drug re-
sidual and, therefore, the number of healthcare workers at risk 
of exposure is underestimated. 
The potential for other areas to be contaminated with 
antineoplastic drugs and, in turn, for additional healthcare 
workers to be at risk of occupational exposure is supported by 
the mechanisms of drug contamination spread that have been 
proposed in the literature. Surface contamination may arise as 
early as the facility receiving stage in the hospital medication 
system as it has been documented that drug vials are often 
contaminated on the outside [9-11]. It is also possible that drug 
residue is spread by the footwear of workers or during cleaning 
of floors and that external drug contamination on gloves may 
be transferred to other objects or surfaces [12]. Overall, this sug-
gests a need to examine the healthcare facility as a whole, not 
just the pharmacy and drug administration units, to determine 
the extent of antineoplastic drug contamination from the point 
at which the agents are received at the facility through to dis-
posal of or excretion. To our knowledge, no existing literature 
has investigated this issue.
The current study aims to identify surfaces throughout the 
hospital medication system whereby antineoplastic drug con-
tamination may be possible and to ascertain the various health-
care job categories that may be at risk of dermal exposure to 
antineoplastic drugs via contact with the contaminated surfaces 
- not just drug administration nurses and pharmacy personnel. 
Materials and Methods
Selection of participating sites
Participating sites were selected from healthcare facilities situ-
ated within the Metro Vancouver area of  British Columbia, 
Canada that prepare and administer CP, the marker drug inves-
tigated in this study. The sites finalized for inclusion were deter-
mined by asking a pharmacy member from each participating 
health administrative authority which of  their facilities is the 
largest users of  CP on an annual basis (based on overall fre-
quency of compounding). In total, 5 major acute care hospitals 
and 1 cancer treatment centre participated in the study.
Informant interviews
Interviews with key informants were conducted in order to un-
derstand the site-specific hospital medication system and to pre-
dict how and where a worker may be exposed to antineoplastic 
drugs. Key informants included supervisors/managers, clinical 
nurse leaders, and team leaders such as the senior pharmacy 
technician. At all sites, the initial interview was conducted in 
the pharmacy department as their personnel would be familiar 
with how the drugs arrive at their department and where the 
prepared drugs are transported for eventual administration. 
Subsequently, additional interviews were scheduled with those 
departments identified by the pharmacy informant as being 
part of  the hospital medication system. All departments at 
each site involved in the hospital medication system were inter-
viewed with the exception of housekeeping which is operated 
by the same external contractor at each site; the company de-
clined to participate in the study.
The duration of each interview was at least twenty min-
utes. All interviewees were asked a series of standard questions 
related to the shift when antineoplastic drugs are primarily 
handled, prepared or administered, circumstances under which 
workers may be exposed to antineoplastic drugs, and the likely 
job categories which may be at risk of exposure. In addition, 
pharmacy personnel were interviewed about their understand-
ing of the hospital medication system at their site. 
Site observations
Passive site observations at each site were conducted by mem-
bers of  the research team to visually establish the hospital 
medication system and to identify which surfaces/objects may 
be contaminated with antineoplastic drugs as well as those job 
categories potentially at risk of  dermal exposure via contact 
with the contaminated surfaces [13]. Employees were consid-
ered “at-risk” if  they physically handled the drugs, contacted 
a potentially drug-contaminated surface/object, or used an 
object previously touched by another worker suspected of hav-
ing drug-contaminated hands/gloves. A standard observation 
checklist was developed and used to record: a) the surfaces/
objects which came into contact with the drug products, b) the 
job category of the worker that contacted the drugs and/or the 
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contaminated surfaces and c) the associated frequency of con-
tact of surfaces/objects for each worker.
At all sites, the observations began in the pharmacy de-
partment where antineoplastic drug preparation took place. We 
then followed the drugs as they were transported to the unit 
where they would be administered. Where prepared drugs were 
delivered to more than one unit, we randomly selected one unit 
to follow the drug. We conducted observations of  the other 
unit(s) on separate occasions. There was considerable variation 
with respect to delivery times of the antineoplastic drugs to the 
healthcare facility. To accommodate this, we scheduled site vis-
its to specifically observe the receiving process but did not nec-
essarily review other areas of the hospital medication system. 
Overall, in order to understand the entire hospital medica-
tion system, each site was observed on at least 5 separate occa-
sions over a course of twelve months starting in June 2009. For 
each site visit, at least 1 task cycle was observed in each depart-
ment. By performing repeated observations the sequence of 
each site’s hospital medication system was determined and the 
job categories with potential risk of exposure to antineoplastic 
drugs were identified. 
Surface sampling and analyses
The contact frequency of a surface/object was averaged over 
the number of observation periods at each site and then ranked 
by order of frequency for each stage of the hospital medication 
system. At each participating site, the top 5 most frequently 
contacted surfaces from the drug preparation and drug admin-
istration stage were selected for sampling and the top 3 most 
frequently contacted surfaces were sampled from all other 
hospital medication system stages. The rationale for sampling 
a varying number of surfaces is that drug preparation and drug 
administration are more complex tasks with greater variability 
than other stages and therefore more surfaces/objects are con-
tacted overall. Surfaces were sampled and analyzed according 
to a previously described procedure [14]. Wipes were analyzed 
for the amount of  CP present using high-performance liquid 
chromatography-tandem mass spectrometry and results report-
ed in nanograms per wipe (ng/wipe).
Data analysis
A histogram was developed for the type and frequency of sur-
faces contacted at each stage. Summary statistics are presented 
for the drug contamination levels found at each stage of  the 
medication circuit. Data were analyzed and figures generated 
using SPlus 8.0 for Windows (Insightful Corp., Seattle, WA, 
USA).
Theory
A thorough understanding of  the medication system within 
a hospital is necessary to determine those surfaces/objects 
throughout the facility which may be contaminated with an-
tineoplastic drugs. In turn, it is then possible to ascertain the 
various categories of healthcare workers that may contact the 
aforementioned surfaces/objects as dermal exposure is the 
primary route of occupational exposure to antineoplastic drugs 
[15-17]. Subsequently, this information can be used to provide 
guidance in developing an appropriate sampling strategy to as-
sess occupational exposure to antineoplastic drugs of all at-risk 
healthcare job categories as part of a future study.
Fig. 1. Overview of the hospital medication system of antineoplastic drugs at the participating facilities.
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Results
General hospital medication system
As shown in Fig. 1, the general sequence of the hospital medi-
cation system for each of the participating facilities has a mini-
mum of the following 6 stages: 1) delivery of the antineoplastic 
drugs to the facility, 2) drug preparation, 3) transport to ward, 4) 
drug administration, 5) disposal and, 6) waste retrieval. As dis-
posal of the waste containers and waste retrieval is performed 
by contracted companies that declined to participate in the 
study, more specific details for these 2 steps were unavailable. 
Description of participating facilities
Table 1 provides a descriptive summary of each of the partici-
pating facilities. All facilities are acute care hospitals except Site 
F which is a cancer centre. Sites B, E and F have the drugs ini-
tially delivered to the shipping/receiving department whereas 
the remaining sites have the drugs delivered directly to the 
pharmacy department. The antineoplastic drugs are prepared 
in dedicated isolation rooms situated in the pharmacy depart-
ment, except at Site D where they are prepared adjacent to an 
area for drugs that are not used for chemotherapy. 
The prepared drugs are delivered by various job categories 
to the administration wards, with one site (Site F) having up to 
3 different job categories performing this task. Drugs are either 
administered in an out-patient clinic or within in-patient wards. 
The antineoplastic drugs are administered in 3 wards at Sites D 
and E. In all instances, the antineoplastic drugs are disposed of 
within the pharmacy (the manufacturers’ vials) as well as in the 
drug administration wards (the intravenous bags). The “notes” 
section of Table 1 shows that each facility is designed slightly 
differently from the others. In most instances, the pharmacy, 
where drug preparation takes place, is situated on a different 
floor from where the drug administration takes place.
Contact frequency of work surfaces/objects
Fig. 2 displays the frequency of surfaces that came into contact 
with antineoplastic drugs and/or potentially drug-contaminat-
ed surfaces contacted by healthcare staff  for each stage of the 
medication system. The box cutter is the most frequently con-
tacted object during drug delivery as it is used to open packages 
of drug shipments.
Table 1. Description of participating facilities
Site A B C D E F
Type Hospital Hospital Hospital Hospital Hospital Cancer centre
1. Drug Delivery (how 
vials are delivered 
from manufacturer)
Direct to phar-
macy
Via shipping/ 
receiving to 
pharmacy
Direct to 
pharmacy
Direct to pharmacy Via shipping/ receiv-
ing to pharmacy
Via shipping/ 
receiving to 
pharmacy
2. Drug Preparation 
(where drugs are 
prepared)
In isolated 
room*
In isolated 
room
In isolated 
room
In non-isolated 
room
In isolation room In isolation room
3. Transport to ward 
(job category tasked 
with transport)
By porter By pharmacist By ward aide By porter or ward 
aide
By porter or nurse By nurse or unit 
clerk or phar-
macy personnel
4. Drug administra-
tion (type of patient 
ward)
1 out-patient 
clinic
1 out-patient 
clinic
1 out-patient 
clinic
2 in-patient wards; 
1 out-patient 
clinic
1 in-patient wards; 2 
out-patient clinics
1 in-patient ward; 
1 out-patient 
clinic
5. Drug disposal 
(department where 
disposal occurs)
Pharmacy and 
out-patient 
clinic
Pharmacy and 
out-patient 
clinic
Pharmacy 
and out-
patient 
clinic
Pharmacy and 
drug administra-
tion wards
Pharmacy and drug 
administration 
wards
Pharmacy and 
drug adminis-
tration wards
Notes (unique fea-
tures of each site)
Pharmacy and 
out-patient 
clinic are 
on different 
floors
Pharmacy is 
adjacent 
to the out-
patient clinic
Pharmacy 
and out-
patient 
clinic are 
on different 
floors
Drug administra-
tion wards are in 
a separate build-
ing from phar-
macy on three 
different floors 
In-patient ward is 
on same floor as 
pharmacy; out-
patient clinics are in 
a separate building 
from pharmacy
Out-patient clinic 
on same floor 
as pharmacy; in-
patient ward is 
one floor below 
the pharmacy
*Isolated: room is designated strictly for antineoplastic drug preparation, non-isolated: room is open-concept with biological safety cabinets 
for preparing antineoplastic drugs and other hoods for preparing non-cytotoxic drugs.
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With respect to drug preparation, the biological safety 
cabinet is the most frequently contacted surface as antineoplas-
tic drugs are prepared in these cabinets at all sites. The next 
most frequently contacted object during drug preparation is the 
writing instrument found inside the biological safety cabinet. 
The writing instrument is used by the Pharmacy Technician to 
label the prepared drugs and/or verify drug dosages. Following 
these two surfaces/objects, there is a great deal of  variability 
with respect to what is contacted and how frequently they are 
contacted.
In the third stage of the medication circuit, drug transport 
within the facility, Fig. 2 shows that the bin where the prepared 
drugs are held for pick up is the most frequently contacted sur-
face.
During drug administration the intravenous pump is the 
object that is most contacted by workers because virtually all 
of the drugs observed were in solution form and had to be ad-
ministered intravenously using the mechanical pump. Similar 
to the drug preparation stage, there is a subsequent assortment 
of surfaces which are contacted across the sites during drug ad-
ministration. 
Surface contamination levels
Of the 275 surface samples collected at the participating sites, 
180 (65%) were less than the limit of detection. Table 2 sum-
marizes the CP contamination levels and reveals detectable 
levels of residual drug contamination at each stage of the medi-
cation circuit. 
Job categories at risk of exposure
Table 3 summarizes the stages of the hospital medication sys-
tem with the corresponding job categories that may be at risk 
of  exposure at each of  the participating sites. The pharmacy 
receiver, pharmacy technician, pharmacist, and nurse are po-
tentially exposed to antineoplastic drugs at all sites. During 
transport of the prepared drugs to the ward, various job catego-
ries are at risk of exposure via handling of the antineoplastic 
drugs. Among the stages of the medication hospital medication 
system, drug administration has the most job categories (six) at 
potential risk of exposure.
With respect to the disposal of  the drug products, Site 
E had a unique job category known as “biopackers” who are 
responsible for transferring the sealed waste containers from a 
holding area to a waste disposal room, where the containers 
would subsequently be picked-up by a waste disposal company.
Based on the information provided by the key personnel 
during the interviews, it is estimated that over 500 workers at 
the six participating sites may have been occupationally ex-
posed. The distribution of the various job categories at each site 
Fig. 2. Surface contact frequency by hospital medication system 
stage. BSC: biological safety cabinet, IPA: isopropyl alcohol, IV: 
intravenous, Pt: patient.
Table 2. Surface contamination levels at each stage of the hospital medication system
1. Drug delivery 2. Drug preparation 3. Transport 4. Drug administration
Number of samples 46 85 30 114
Number of samples < Limit of detection 41 38 21 80
Mean (ng/wipe) 3.20   51.18   9.68   7.40
Standard deviation (ng/wipe) 1.33 164.22   8.19 11.50
Minimum (ng/wipe) 1.29     0.38   0.44   0.41
Maximum (ng/wipe) 4.95 988.47 28.99 52.69
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that are potentially exposed is shown in Table 4.
Discussion
We hypothesized that contamination of surfaces with antineo-
plastic drugs occurs at every stage of the hospital medication 
system. Through observation and subsequent sampling of the 
most frequently contacted surfaces, our study results prove that 
surface contamination, and hence the potential for occupation-
al exposure to antineoplastic drugs, does occur at every stage 
of the hospital medication system. Those job categories most 
likely to be exposed are pharmacy receiver, pharmacy techni-
cian, pharmacist, and nurse as these cohorts were consistently 
observed to be in contact with antineoplastic drugs at each of 
the 6 participating sites. Up to 11 job categories (not includ-
ing housekeeping) per site are potentially at risk of exposure. 
The characteristics of a site that results in the most number of 
job categories exposed include: a) having the drugs initially 
delivered to the shipping/receiving department (as opposed to 
directly to the pharmacy), b) having multiple job categories re-
Table 3. Observed job categories and associated tasks with potential for dermal exposure at each healthcare facility
Potentially at-risk job categories 
at each stage of the hospital 
medication system
Sites where the following tasks with potential drug exposure were observed
Handles drugs* Prepares drugs Administers drugs
Contacts drug-
contaminated surfaces
1. Delivery
Shipper/Receiver 3 sites (B, E, F)† 0 sites 0 sites 0 sites
Pharmacy receiver All 6 sites 0 sites 0 sites All 6 sites
2. Drug preparation
Pharmacy technician All 6 sites All 6 sites 0 sites All 6 sites
Pharmacist All 6 sites 0 sites 0 sites All 6 sites
3. Transport to ward
Porter 3 sites (A, D, E) 0 sites 0 sites 3 sites (A, D, E)
Nurse 2 sites (E, F) 0 sites 0 sites 2 sites (E, F)
Pharmacist 2 sites (B, F) 0 sites 0 sites 2 sites (B, F)
Unit clerk 1 site (F) 0 sites 0 sites 1 site (F)
Ward aide 2 sites (C, D) 0 sites 0 sites 2 sites (C, D)
4. Drug administration
Nurse All 6 sites 0 sites All 6 sites All 6 sites
Volunteer 0 sites 0 sites 0 sites 2 sites (A,B)
Unit clerk 3 sites (D, E, F) 0 sites 0 sites All 6 sites
Clinic pharmacist 1 site (A) 0 sites 0 sites 2 sites (A, C)
Dietician 0 sites 0 sites 0 sites 2 sites (A,B)
Oncologist 0 sites 0 sites 0 sites 1 site (A)
5. Disposal
Nurses All 6 sites 0 sites 0 sites All 6 sites
Pharmacist 5 sites (A, B, D, E, F) 0 sites 0 sites 5 sites (A, B, D, E, F)
Pharmacy technician 1 site (C) 0 sites 0 sites 0 sites
Biopacker 1 site (E) 0 sites 0 sites 1 site (E)
*Includes shipments, drug vials, intravenous bags and waste containers.
†Letters refers to participating sites as per Table 1.
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sponsible for transport of prepared drugs to the ward(s) and, c) 
having more than one drug administration unit.
Our study builds on the list of healthcare workers exposed 
to antineoplastic drugs due to handling activities developed 
by the National Institute for Occupational Safety and Health 
(NIOSH) [18]. In addition to the cohorts specified by NIOSH, 
our results suggest that it is reasonable to add the following per-
sonnel to the existing list: unit clerk, porter, ward aide, dietitian, 
oncologist, biopacker and shipper/receiver.
Although our study primarily focused on occupational 
exposure, it is conceivable that patients, family members, and 
friends are also at risk of exposure, as suggested by Sorsa et al 
Table 4. Number of workers per at-risk job category at participating sites
Department Job category Site A Site B Site C Site D Site E Site F Subtotals
Pharmacy Pharmacy technician 6 FT; 0 FT; 2 PT 13 FT; 3 PT 7 FT; 2 PT 27 FT; 4 PT 7 FT; 4 PT 60 FT; 15 PT
6.0 FTE 1.8 FTE 15.1 FTE 7.85 FTE 30.2 FTE 9.0 FTE 69.95 FTE
Pharmacy receiver 3 FT 0 FT; 10 PT 2 FT; 4 FT 3 FT 1 FT 13 FT; 10 PT
3.0 FTE 0.25 FTE 2 FTE 4 FTE 3 FTE 1 FTE 13.25 FTE
Pharmacist 4 FT; 2 PT 1 FT 11 FT; 9 PT 6 FT; 1 PT 31 FT; 7 PT 7 FT; 5 PT 66 FT; 25 PT
4.8 FTE 1 FTE 16.89 FTE 6.5 FTE 35.7 FTE 9.5 FTE 74.39 FTE
Drug adminis-
tration unit
Nurse 4 PT 1 FT; 6 PT 6 FT; 1 PT 60 FT; 11 PT 54 FT; 26 PT 26 FT; 16 PT 147 FT; 64 PT
2.60 FTE 4.0 FTE 6.0 FTE 67.2 FTE 73.77 FTE 35.10 FTE 188.67 FTE
Pharmacy technician 1 PT N/A N/A N/A N/A N/A 1 PT
(oncology unit) 1 FTE 1 FTE
Clinical pharmacist 1 FT N/A 1 FT N/A N/A N/A 2 FT 
(oncology unit) 1 FTE 1.0 FTE 2 FTE
Volunteer 7 PT 10 PT N/A N/A N/A N/A 17 PT 
0.8 FTE 5.0 FTE 5.8 FTE
Unit clerk 2FT; 1 PT 3 FT; 1 PT Could not 
obtain
5 FT; 4 PT 1FT; 1PT 6 FT; 7 PT 17 FT; 14 PT
2.40 FTE 3.0 FTE 7. 83 FTE 1.20 FTE 8.0 FTE 22.43 FTE
Oncologist 1 FT; 2 PT N/A N/A N/A N/A N/A 1 FT; 2 PT
1.8 FTE 1.8 FTE
Ward aide N/A N/A 1 FT 2 FT N/A 1 FT 4 FT 
1.0 FTE 2 FTE 1 FTE 4.0 FTE
Dietitian 2 PT 1 PT N/A N/A N/A 3 PT 
0.5 FTE 0.4 FTE 0.9 FTE
Patient trans-
port
Porter 8 FT; 3 PT N/A N/A 2 FT; 1 PT 44 FT; 10 PT 54 FT; 14 PT
9.3 FTE 2.8 FTE 51.0 FTE 33.1 FTE
Shipping/re-
ceiving
Shipper/receiver N/A Could not obtain N/A Could not 
obtain
3 FT 4 FT 7 FT 
3 FTE 4.0 FTE 7 FTE
TOTALS 357 FT; 162 PT
424.29 FTE
FT: full-time, PT: part-time, FTE: full-time equivalent, N/A: not applicable to the site.
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[19]. This is because communal objects such as elevator but-
tons, door handles and patient chair side tables, which may be 
contacted by non-hospital personnel, were found to be con-
taminated in our study.
The finding of surface contamination throughout the en-
tire hospital medication system implies that healthcare workers 
contacting these surfaces are at risk of exposure via the dermal 
route. Our calculations suggest that more than 500 workers at 
the 6 participating sites are at risk. If  this figure were extrapo-
lated to all sites where antineoplastic drugs are handled in the 
province of British Columbia, then a conservative estimate of 
the number of healthcare workers at risk is 3,500 [20]. Given 
the number of workers potentially exposed to these hazardous 
agents, members of  our research team are currently conduct-
ing a quantitative exposure assessment of those job categories 
believed to be at risk.
Among the study limitations, we were unable to ascertain 
the frequency of contact associated with housekeeping person-
nel as they are employees of a company that declined to par-
ticipate in our study. We can surmise that housekeepers would 
contact the cytotoxic waste containers but cannot estimate the 
contact risk for other surfaces. As waste containers were found 
to have detectable levels of  drug residue, we can infer that 
housekeepers do indeed face an exposure potential. Another 
limitation is the possible absence of certain job categories and/
or surfaces in our results despite repeated site observations. 
Nevertheless, since we performed the site observations on mul-
tiple days and observed different individuals, we are confident 
that we have captured a reasonably representative understand-
ing of the hospital medication system, the job categories com-
monly at risk of  exposure and the potentially contaminated 
work surfaces at each site. 
To our knowledge, this is the first study of its kind to ex-
amine the occupational exposure potential to antineoplastic 
drugs throughout the entire hospital medication system of  a 
healthcare facility. Based on the study results, we are now able 
to develop an appropriate sampling strategy for all job catego-
ries considered at risk of exposure. This is important in order to 
validate that existing control measures are not only appropriate 
in reducing occupational exposure to antineoplastic drugs but 
that they are comprehensive in scope to protect all at-risk job 
categories within a healthcare facility. 
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